Nakajima Y - Search Results

1

Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.

Nakajima Y, Nogami K, Yada K, Furukawa S, Noguchi-Sasaki M, Hirata M, Shima M. Nakajima Y, et al. Thromb Haemost. 2020 Jun;120(6):968-976. doi: 10.1055/s-0040-1710315. Epub 2020 May 8. Thromb Haemost. 2020. PMID: 32384547

2

Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.

Nakajima Y, Nogami K, Yada K, Ogiwara K, Furukawa S, Shimonishi N, Shima M. Nakajima Y, et al. Haemophilia. 2019 May;25(3):e174-e179. doi: 10.1111/hae.13725. Epub 2019 Mar 13. Haemophilia. 2019. PMID: 30866149

3

Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.

Nakajima Y, Nogami K, Yada K, Kawamura T, Ogiwara K, Furukawa S, Shimonishi N, Takeyama M, Shima M. Nakajima Y, et al. Int J Hematol. 2020 Mar;111(3):369-377. doi: 10.1007/s12185-019-02782-z. Epub 2019 Nov 18. Int J Hematol. 2020. PMID: 31741138

4

Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.

Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Furukawa S, et al. Among authors: nakajima y. Br J Haematol. 2020 Sep;190(5):727-735. doi: 10.1111/bjh.16574. Epub 2020 Mar 12. Br J Haematol. 2020. PMID: 32162680 Free article.

5

A microchip flow-chamber assay screens congenital primary hemostasis disorders.

Nakajima Y, Yada K, Ogiwara K, Furukawa S, Shimonishi N, Shima M, Nogami K. Nakajima Y, et al. Pediatr Int. 2021 Feb;63(2):160-167. doi: 10.1111/ped.14378. Epub 2020 Dec 5. Pediatr Int. 2021. PMID: 32640065

6

The C-terminal acidic region in the A1 domain of factor VIII facilitates thrombin-catalyzed activation and cleavage at Arg³⁷².

Nakajima Y, Nogami K. Nakajima Y, et al. J Thromb Haemost. 2021 Mar;19(3):677-688. doi: 10.1111/jth.15201. Epub 2020 Dec 26. J Thromb Haemost. 2021. PMID: 33369157 Free article.

7

Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis.

Mizumachi K, Tsumura Y, Nakajima Y, Koh K, Nogami K. Mizumachi K, et al. Among authors: nakajima y. Int J Hematol. 2021 Jun;113(6):930-935. doi: 10.1007/s12185-021-03095-w. Epub 2021 Feb 10. Int J Hematol. 2021. PMID: 33566316

8

Acidic Region Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg1689.

Nakajima Y, Minami H, Nogami K. Nakajima Y, et al. Thromb Haemost. 2021 Oct;121(10):1274-1288. doi: 10.1055/s-0041-1723996. Epub 2021 Feb 16. Thromb Haemost. 2021. PMID: 33592631

9

Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.

Nakajima Y, Tonegawa H, Noguchi-Sasaki M, Nogami K. Nakajima Y, et al. Int J Hematol. 2021 Jun;113(6):789-796. doi: 10.1007/s12185-021-03108-8. Epub 2021 Feb 26. Int J Hematol. 2021. PMID: 33635530

10

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.

Takeyama M, Furukawa S, Yada K, Ogiwara K, Shimonishi N, Nakajima Y, Mizumachi K, Noguchi-Sasaki M, Shima M, Nogami K. Takeyama M, et al. Among authors: nakajima y. Thromb Haemost. 2021 Oct;121(10):1289-1298. doi: 10.1055/s-0041-1725009. Epub 2021 Feb 28. Thromb Haemost. 2021. PMID: 33641138

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,671 results

Search Page

Filters